Cytosorbents Crp (CTSO)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $15.35M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cytosorbents Crp (CTSO) Financials: Revenue, Profit and Cash Flow
Cytosorbents Crp reported revenue of $37.06M for the fiscal year ended Dec 31, 2025, up 4.1% from the year before. That year, net income was -$8.20M with a net margin of -22.1%, operating cash flow was -$12.38M and free cash flow was -$12.54M. The quarter ended Jun 30, 2026 had revenue of $9.63M and net income of -$4.42M.
Revenue and Margins
The operating margin was -39.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $9.53M, a compound annual rate of 16.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $37.06M | +4.1% | 71.5% | -39.8% | -22.1% |
| Dec 2024 | $35.59M | +14.5% | 69.9% | -46.2% | -58.2% |
| Dec 2023 | $31.08M | -10.4% | 70.6% | -102.8% | -94.1% |
| Dec 2022 | $34.69M | -19.6% | 59.8% | -90.9% | -94.6% |
| Dec 2021 | $43.17M | +5.3% | 74.4% | -52.7% | -56.9% |
| Dec 2020 | $41.00M | +64.4% | 73.0% | -25.3% | -19.1% |
| Dec 2019 | $24.95M | +10.9% | 70.5% | -76.0% | -77.2% |
| Dec 2018 | $22.50M | +48.5% | 66.7% | -69.3% | -76.5% |
| Dec 2017 | $15.15M | +59.0% | 63.6% | -65.0% | -55.8% |
| Dec 2016 | $9.53M | N/A | 58.5% | -120.6% | -123.5% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.06M | $35.59M | $31.08M | $34.69M | $43.17M | $41.00M | $24.95M | $22.50M | $15.15M | $9.53M |
| Cost of revenue | $10.57M | $10.71M | $9.13M | $13.96M | $11.05M | $11.05M | $7.36M | $7.49M | $5.52M | $3.95M |
| Gross profit | $26.49M | $24.89M | $21.95M | $20.73M | $32.12M | $29.95M | $17.59M | $15.01M | $9.63M | $5.57M |
| Research and development | $5.08M | $7.61M | $15.59M | $15.12M | $16.38M | $8.81M | $12.09M | $7.72M | $3.22M | $4.07M |
| Operating income | -$14.75M | -$16.45M | -$31.95M | -$31.52M | -$22.74M | -$10.37M | -$18.97M | -$15.58M | -$9.84M | -$11.49M |
| Net income | -$8.20M | -$20.72M | -$29.25M | -$32.81M | -$24.56M | -$7.84M | -$19.27M | -$17.21M | -$8.46M | -$11.76M |
| EBITDA | -$3.54M | N/A | -$27.88M | N/A | N/A | -$6.78M | -$18.63M | N/A | -$8.09M | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.63M | $8.86M | $9.23M | $9.48M | $9.62M | $8.73M | $9.15M | $8.61M | $8.84M | $8.99M | $3.40M | $8.81M |
| Gross profit | $7.05M | $6.13M | $6.80M | $6.67M | $6.81M | $6.21M | $6.25M | $5.26M | $6.50M | $6.87M | $4.87M | $5.61M |
| Operating income | -$2.64M | -$3.04M | -$4.38M | -$2.86M | -$3.62M | -$3.89M | -$3.40M | -$4.83M | -$3.57M | -$4.66M | -$10.15M | -$7.35M |
| Net income | -$4.42M | -$5.13M | -$5.50M | -$3.17M | $1.95M | -$1.48M | -$7.57M | -$2.77M | -$4.29M | -$6.09M | -$6.57M | -$9.19M |
Balance Sheet
As of Dec 2025, total debt of $16.67M exceeded cash and equivalents by $10.42M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $44.18M | $47.37M | $52.96M | $63.23M | $89.52M | $89.95M | $27.38M | $34.20M | $24.10M | $9.69M |
| Current assets | $20.63M | $21.60M | $25.40M | $33.76M | $64.30M | $82.45M | $20.90M | $28.26M | $20.74M | $7.83M |
| Cash and equivalents | $6.25M | $3.28M | $14.13M | $22.14M | $52.14M | $71.42M | $12.23M | $22.37M | $17.32M | $5.25M |
| Total liabilities | $38.28M | $36.27M | $29.48M | $27.86M | $26.94M | $10.73M | $23.96M | $17.26M | $13.84M | $8.36M |
| Short-term debt | $0 | $452.69K | $2.50M | $0 | $570.57K | $447.49K | $1.67M | $666.67K | $4.00M | $833.33K |
| Long-term debt | $16.67M | $14.00M | $2.54M | $5.00M | $0 | N/A | $13.39M | $9.27M | $5.99M | $4.08M |
| Shareholder equity | $5.90M | $11.11M | $23.48M | $35.37M | $62.58M | $79.22M | $3.42M | $16.93M | $10.26M | $1.34M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $37.96M | $40.56M | $44.18M | $45.75M | $47.99M | $50.78M | $47.37M | $47.80M | $53.43M | $47.07M | $53.26M | $47.58M |
| Total liabilities | $38.71M | $38.37M | $38.28M | $36.73M | $36.40M | $36.24M | $36.26M | $34.80M | $36.69M | $28.14M | $29.99M | $29.06M |
| Cash and equivalents | $4.41M | $4.81M | $6.25M | $7.54M | $10.20M | $11.59M | $3.28M | $5.69M | $8.46M | $8.61M | $14.13M | $8.36M |
| Shareholder equity | -$751.00K | $2.19M | $5.90M | $9.02M | $11.59M | $14.54M | $11.11M | $13.00M | $16.74M | $18.93M | $23.28M | $18.51M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.38M | -$14.43M | -$21.66M | -$28.23M | -$14.01M | -$5.61M | -$16.76M | -$10.84M | -$6.46M | -$6.73M |
| Capital expenditures | $164.00K | $284.00K | $538.12K | $6.09M | $3.64M | $708.39K | $698.16K | $671.97K | $990.67K | $140.72K |
| Free cash flow | -$12.54M | -$14.71M | -$22.19M | -$34.32M | -$17.65M | -$6.32M | -$17.46M | -$11.51M | -$7.45M | -$6.87M |
| Dividends paid | N/A | N/A | N/A | $5.00M | N/A | N/A | N/A | N/A | $335.73K | $0 |
| Investing cash flow | -$415.00K | -$669.00K | -$936.24K | -$6.46M | -$4.28M | -$1.68M | -$1.52M | -$1.52M | -$1.68M | $1.60M |
| Financing cash flow | $9.31M | $9.33M | $14.47M | $4.96M | $715.20K | $66.35M | $8.18M | $17.47M | $20.12M | $5.06M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$583.00K | -$1.16M | -$4.83M | -$2.58M | -$1.51M | -$3.47M | -$2.34M | -$2.46M | -$4.79M | -$4.83M | -$6.41M | -$5.21M |
| Capital expenditures | $14.00K | $11.00K | $108.00K | $17.00K | $37.00K | $2.00K | $69.00K | $152.00K | $17.81K | $45.19K | $95.50K | $142.40K |
| Free cash flow | -$597.00K | -$1.17M | -$4.93M | -$2.59M | -$1.55M | -$3.47M | -$2.41M | -$2.62M | -$4.81M | -$4.87M | -$6.50M | -$5.35M |
Frequently Asked Questions About CTSO
What is Cytosorbents Crp's annual revenue?
Cytosorbents Crp reported revenue of $37.06M for the fiscal year ended Dec 31, 2025.
How fast is Cytosorbents Crp's revenue growing?
Revenue was up 4.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.2%.
Is Cytosorbents Crp profitable?
No. Cytosorbents Crp reported net income of -$8.20M for the fiscal year ended Dec 31, 2025, with a net margin of -22.1%.
How much free cash flow does CTSO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.38M minus capital expenditures of $164.00K produced free cash flow of -$12.54M.
How much debt does Cytosorbents Crp have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $16.67M, short-term debt of $0 and cash and equivalents of $6.25M.
CTSO pages: Overview, Earnings, Forecast, Financials, Competitors